Experts discuss combining radiopharmaceuticals with systemic therapies for advanced prostate cancer

Dr. Pedro Barata and Dr. Johann de Bono presented a discussion on emerging combination strategies that pair radiopharmaceuticals with other systemic treatments for metastatic castration-resistant prostate cancer (mCRPC).

They explained the scientific rationale for combining these agents, noting that radiopharmaceuticals can deliver targeted radiation to tumor sites while systemic drugs address disease outside the radiation field, potentially improving overall disease control.

The conversation highlighted key considerations such as selecting appropriate patients, managing overlapping toxicities, and integrating radiopharmaceuticals into existing treatment sequences.

The discussion is part of a broader educational series that explores various aspects of radiopharmaceutical therapy in mCRPC, including safety, sequencing, and future directions.